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Summary It is extremely difficult to identify the factors which regulate the expression of drug-metabolising
enzymes in man. To address this problem, we have developed a model involving the use of human tumours
grown as xenografts in immune deficient mice. Mice bearing human colon or breast tumours as xenografts
were challenged with a range of compounds, known from animal studies to be inducers of cytochrome P450s
from a variety of gene families. Almost all of the compounds tested could induce human tumour P450
expression, measured either by Western blot or immunohistochemical analysis. Indeed, the levels of P450s
from several distinct gene families or subfamilies including CYP2A, CYP2B, CYP2C, CYP3A and CYP4A
were induced. Of particular interest was the profound induction of human P450s by 1,4 bis 2-(3,5dichloro-
pyridyloxybenzene)(TCPOBOP), a compound which exhibits a marked species specificity in its ability to
induce P450 expression in experimental animals. Induction of a human CYP2B protein by this compound was
confirmed by Northern blot analysis and in situ hybridisation for mRNA, indicating that induction occurred at
the level of transcription. These studies have a variety of implications: they provide a method for approaching
the previously intractable problem of how environmental, hormonal and metabolic factors regulate human
P450 genes and other genes involved in drug metabolism; they demonstrate that human tumours express P450s
constitutively and that the levels of these proteins can be modulated by exogenous agents.
The cytochrome P450-dependent monooxygenases (P450s)
are thought to have evolved as a protective adaptive response
against the toxic effects of environmental chemicals (Nebert
& Gonzalez, 1987; Wolf, 1991). This polymorphic multigene
superfamily of hemoproteins can metabolise a vast number
of lipophilic exogenous compounds, including drugs and
environmental toxins (Guengerich, 1987; Conney, 1982), to
products which can be more readily excreted. Ironically, in
addition to their role in detoxification, P450 enzymes also
play a central role in the conversion of chemical toxins and
procarcinogens to their ultimately toxic or carcinogenic
forms (see Nebert & Gonzalez, 1987; Wolf, 1991). The ability
of P450s to activate chemical toxins has been exploited in
cancer chemotherapy, where a variety of anticancer drugs
require metabolic activation in order to exert their cytotoxic
effects (Powis & Prough, 1987). Understanding the genetic
and environmental factors which regulate human cytochrome
P450 expression is therefore of central importance. For a
variety of reasons, at present there is very little precise in-
formation available on the regulation of these genes in man,
particularly in extra-hepatic tissues.
Animal models have been widely used to study drug
metabolising enzymes and the factors which regulate their
expression. Although these have provided extremely valuable
information, their use is inherently limited by the extent to
which they represent the human system. For example, there
are significant species and strain differences in the expression
and regulation of drug metabolising enzymes (Omenn &
Gelboin, 1984). Indeed, compounds which are potent regula-
tors of these enzymes in one species can have greatly reduced
or no effects in another (Poland et al., 1980). This, together
with genetic considerations, implies that no animal model can
truly represent the enzyme systems found in man (Miles et
al., 1990).
In vitro studies of human P450 gene regulation are difficult
as the expression, and ability to regulate the levels of most of
these proteins by foreign compounds is lost in both primary
hepatocytes and tumour cell lines in culture (Paine, 1990).
This is a particular problem for studying the effects of hor-
monal and other metabolic factors on P450 gene expression
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(Lindberg et al., 1991) and, with the exception of regulation
of CYP1A gene expression by polycyclic aromatic hydrocar-
bons such as TCDD (Pasenen et al., 1988), there have been
few reports on P450 regulation in cell lines derived from
extra-hepatic tissues (Falzon et al., 1986; Stanley et al., 1992).
In view of these limitations, we have tested a model in which
human gene regulation by both endogenous and exogenous
modulators can be studied in vivo. In this system, human
tumours are grown as xenografts in immune deficient mice.
This model, which has been widely used to evaluate the
response of human tumours to anticancer drugs, is taken as
an accurate representation of the behaviour of these com-
pounds in human tumour tissues (Berger et al., 1991). We
describe the use of this system to study the effects of a range
of compounds, known to modulate P450 expression in exper-
imental animals, on human tumour P450 levels. The com-
pounds chosen included agents which exhibit profound
species differences in their inductive effects in experimental
animals, such as TCPOBOP and dexamethasone (Poland et
al., 1989; Meehan et al., 1988).
Materials and methods
Chemicals
Unless otherwise indicated, all chemicals were purchased
from either Sigma Chemical Co. Ltd., Poole, Dorset, or
BDH Ltd., Burnfield Avenue, Thornliebank, Glasgow, and
were of analytical grade or better. TCPOBOP was synthe-
sised according to a modified version of the method of
Poland et al. (1980). Two molar equivalents of 2,3,5-
trichloropyridine were added to one molar equivalent of
hydroquinone in DMSO. The solution was heated to 65$C
under reflux for 30 min before the addition of 30 mM NaOH
to make a 50% aqueous solution. After a further 2 h at
110°C, the solution was cooled to room temperature and the
solid product collected by the addition of 10% NaOH and
subsequent filtration. The product was washed with distilled
water to remove any aqueous impurities and re-crystallised
from carbon tetrachloride before analysis by nuclear magne-
tic resonance spectroscopy and mass spectrometry to confirm
the chemical structure and molecular mass.
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Animals, tumours and treatments
The tumours NCH (infiltrating ductal carcinoma of the
breast) and GFH (adenocarcinoma of colon) were main-
tained as xenografts growing sub-cutaneously in the flanks of
6-12-week-old specific pathogen free Nu-Nu mice of mixed
genetic background and were passaged as required. These
animals were maintained as previously described (Malik et
al., 1989). The tumours were established from primary un-
treated human tumours without prior tissue culture and were
grown as xenografts to a diameter of 1 cm. Mice were then
assigned at random to treatment groups and treated intra-
peritoneally according to the following induction proto-
cols:
Controls were either untreated or received vehicle only.
P-naphthoflavone, (80 mg kg-'), 3-methylcholanthrene, (100
mgkg-'), clofibric acid, (200 mgkg-'), phenobarbital, (80
mg kg-') and dexamethasone (100 mgkg-') were dosed daily
for 3 days before use. TCPOBOP, (3 mgkg-1), were dosed as
a single injection 4 days before use. Microsomal samples
were prepared from liver and tumour tissue by differential
centrifugation (Meehan et al., 1988) and were stored at
- 40°C until required.
Immunoblotting
SDS/polyacrylamide gel electrophoresis (SDS/PAGE) follow-
ed by immunoblotting was as previously described (Towbin
et al., 1979; Lewis et al., 1988). Nitrocellulose filters were
probed with polyclonal antisera to various rat liver cyto-
chrome P450s. These antibodies have been extensively char-
acterised in mouse and human microsomal samples (Meehan
et al., 1988; Forrester et al., 1992) and the reactivity and
isozyme specificity of the antisera demonstrated by immuno-
blot analysis with expressed recombinant human P450 pro-
teins (Forrester et al., 1992). The antibodies used were to rat
CYP1A2 (reactive with both the CYPlAl and CYP1A2
proteins), CYP2A1, CYP2B1, CYP2C6, CYP3A1 and
CYP4A1. The P450 nomenclature system used throughout
this manuscript is that ofNebert et al. (1991). After visualisa-
tion of the immunoreactive polypeptides using horseradish
peroxidase-labelled second antibody and 4-chloro-1-naphthol
as substrate, the signal was enhanced with '251-protein A
(Amersham International plc) and subsequent autoradio-
graphy (Kodak X-Omat AR5 X-ray film) at - 70°C. In
certain cases, where the levels of expressed protein were
particularly low, the Amersham ECL detection system was
used.
Northern blotting
RNA was isolated from liver and tumour samples and
Northern blot analysis carried out as previously described
(Forrester et al., 1992). Following pre-hybridisation at 65°C
(5 x SSC, 2 x Denhardts, 10% dextran sulphate, 0.2% SDS,
0.2% sodium pyrophosphate) for 3 h, the filter was hy-
bridised overnight with a cDNA probe to human cytochrome
P450 CYP2B6. Blots were washed at 65°C (0.3 M sodium
chloride, 0.03 M trisodium citrate, pH 7.4, 0.1% SDS, 0.1%
sodium pyrophosphate) and bands subsequently visualised by
autoradiography. 10 x SSC is 1.5 M sodium chloride 150 mM
sodium citrate.
Immunohistochemistry and in situ hybridisation
Sections for immunohistochemistry were cut at 3gsm, dewax-
ed in xylene and rehydrated through graded alcohols. Slides
were washed several times in buffer (100 mM Tris, 0.1%
Tween 20, 5% normal goat serum) before overnight incuba-
tion with rabbit polyclonal P450 antisera (diluted 1:50 in
buffer), washed (3 x 10min) and incubated (30 min) with
biotinylated goat anti-rabbit IgG (1:500 in buffer). Sections
were then exposed to streptavidin-peroxidase conjugate
(Dako, Ltd. UK) for 30 min and then developed with 3,3'
diaminobenzidene and lightly counterstained with haematoxy-
lin.
In situ hybridisation was performed essentially according
to Herrington et al. (1990), with the following modifications:
Formalin fixed sections were dewaxed and then permeabilised
in 0.2 M HCI followed by 0.3% Triton-X100 in phosphate-
buffered saline. Proteinase K was used at 10-20 mgmlh- and
sections were postfixed in 0.4% paraformaldehyde. After 1 h
at 37°C in prehybridisation buffer (0.6 M NaCl, 10% dextran
sulfate, 30% deionised formamide, 0.1% sodium pyrophos-
phate, 0.2% polyvinylpyrrolidone, 0.2% Ficoll), 20-40 ng of
biotinylated probe was incubated overnight at 37°C. Detec-
tion of oligonucleotide binding was achieved using a mouse
anti-biotin antibody, followed by alkaline phosphatase labell-
ing using nitroblue tetrazolium (NBT)/5-bromo-4-chloroin-
dolyl phosphate (BCIP), overnight at 4°C for visualisation.
The oligonucleotides used were an 18mer from Exon 2
(bp 112-130) of the cDNA sequence of the human CYP2B6
gene, (5'CCCATATTTCTCTCGGAA 3' antisense); (5'TTC-
CGAGAGAAATATGGG 3' sense). These oligonucleotides
had 6 mismatches relative to the mouse Cyp2b9 sequence.
Three biotin molecules were added at the 5' end of each
oligonucleotide using a monomer developed by Link Techno-
logies, Cumbernauld, Scotland.
Results
A variety of compounds, known to induce P450s from a
range of gene families or subfamilies in animal models, was
administered to mice bearing either human breast or colon
tumours as xenografts. The effectiveness of the induction
protocol was confirmed by demonstrating that the predicted
changes in murine hepatic cytochrome P450 gene expression
had occurred (data not shown).
Control untreated xenograft samples had extremely low
P450 content. However, a protein which reacted with the
antibody to CYP2A1 was identified by Western blot analysis
(Figure 1). This protein had a different mobility to recom-
binant human CYP2A6, which has been associated with
hepatic coumarin hydroxylase activity (Miles et al., 1990;
Yamano et al., 1990). Very low levels of proteins reacting
with antibodies to CYP2B1 and CYP2C6 were detected in
the colon tumour using the highly sensitive ECL detection
system (not shown). The relative mobility of the protein
detected with the CYP2B1 antibody (54.5 kD) was different
to human CYP2B6 (51.0kD). The mobility of the protein
detected with anti CYP2C6 was the same as human CYP2C8
(54.5 kD).
Tumour cytochrome P450 content was significantly altered
by the administration of several of the P450-inducing agents
tested (Figure 1). 3-Methylcholanthrene (3-MC) and P-
naphthoflavone (P-NF) are both well characterised inducers
of P450 proteins in the CYPIA and CYP2A gene families
(Guengerich, 1987). Both of these compounds could induce
the level of a CYPIA protein, probably CYPlAI, within
both the colon and breast tumour tissues. The level of a
protein reacting with the CYP2A1 antibody (Figure 1, lower
band) was also increased 2-3-fold and stronger upper band
approximately 5-fold in the breast and colon samples respec-
tively, by both 3-MC and P-NF. A third protein with a
higher apparent molecular weight (55.5 kD), was also slightly
induced by these compounds in the breast, but not the colon
tissue. Interestingly, in further experiments using ECL as the
detection system, 3-MC also caused slight induction (2-3-
fold) in the level of the protein reacting with the antibody to
CYP2B1 (data not shown).
TCPOBOP and dexamethasone are potent 'phenobarbital-
like' inducing agents in the mouse, but have virtually no
effect on the expression of the major phenobarbital-inducible
isozymes in the rat (Poland et al., 1980; Meehan et al., 1988).
The ability of these two compounds to induce human tumour
P450 levels was compared to the effects of phenobarbital.
TCPOBOP, at a dose of 3 mg kg-l was a potent modula-
tor of human P450 expression, inducing proteins in the
CYP2A, CYP2B, CYP2C, CYP3A and CYP4A gene families.
In breast tissue, the constitutively expressed CYP2A formREGULATION OF CYTOCHROME P450 GENE EXPRESSION 59
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Figure 1 Induction of cytochrome P450 expression in human breast and colon tumour xenografts. Human colon a, or breast b,
tumours were grown as xenografts in immune deficient mice to a diameter of 1 cm. Animals were then treated intra-peritoneally
with a variety of compounds, as described in Materials and methods. Microsomal fractions were prepared from tumour samples
and analysed for cytochrome P450 content by Western blotting using the antibodies shown in the left hand track. FifteenAg of
microsomal protein was loaded per track. Following transfer to nitrocellulose, antibody incubations were carried out as described
previously (Meehan et al., 1988), using '251-Protein A for visualisation. C = control, MC = 3-methylcholanthrene, NF = P-
naphthoflavone, Cl = clofibric acid, T = TCPOBOP, D = dexamethasone, PB = phenobarbital, S = purified rat P450 standards to
the CYP1A2, CYP2A1, CYP2B1, CYP2C6, CYP3A4 and CYP4A1 isozymes respectively. HLM is a human liver microsomal
sample. The relative mobility of recombinant human P450s are shown in the right hand track and were aligned from a blot where
the liver and tumour samples were run on the same gel.
(lower band) and that slightly induced by 3-MC (mr 555 kD)
were both markedly induced. In colon tissue, only the major
51.5 kD protein (band 2) was induced. Proteins reacting with
antisera to CYP2B1 were markedly increased on TCPOBOP
treatment in both the breast and colon tissues, with the
induction of CYP2B in the colon being particularly pro-
nounced. This induced protein had the same mobility as the
constitutively expressed form and appears to be distinct from
CYP2B6. Whether this protein is CYP2B7 or a novel cyto-
chrome P450 isozyme is currently being investigated. Proteins
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CYP3A4
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reacting with the CYP2C6 and CYP3Al antibodies were also
induced in the xenograft tissue by TCPOBOP. Based on
mobilities of these induced proteins they may be CYP2C8
and CYP3A4 respectively. However, further work is required
to clarify this. Perhaps the most surprising effect of
TCPOBOP was the profound increase in the expression of a
protein reacting with the antibody to CYP4A1. This induc-
tion was particularly pronounced in the breast tumour, but
was also observed in the colon samples (data not shown).
In a similar manner to TCPOBOP, dexamethasone also
induced proteins in the CYP2B gene family in both the
breast and colon tumours (Figure 1) but did not increase the
levels of P450's in the CYP3A gene family (Figure 1 and not
shown). Interestingly, this compound also caused a marked
induction of the protein reacting with the CYP4A antibody
in colon but not in breast tissue. Relative to TCPOBOP and
dexamethasone, phenobarbital was much less effective as an
inducing agent in the xenograft tumours, but did cause some
increase in the levels of CYP2A and CYP2B proteins in both
tumours and CYP4A in the breast xenograft. Clofibric acid
had very little effect on tumour P450 expression but did
appear to induce the protein reacting with the CYP2A anti-
body (lower band). This compound did not induce proteins
reacting with the antibody to CYP4A1.
Localisation ofthe inducedproteins
A potential problem in the use of tumour xenografts to study
human gene regulation is the possibility that the observed
changes in gene expression are due to infiltration of the
tumour with cells of the host and that the enzymes studied
are, in fact, murine. Immunohistochemical studies with P450
polyclonal antisera unequivocally demonstrated that the
induced proteins are localised within malignant human
epithelial cells rather than mouse derived tissues (Figure 2).
The cells staining positive with the antisera were morpho-
logically malignant on histopathological examination.
Tumour cells were derived from a multiply passaged cell line
and no significant murine stroma was visible (A.H. Wyllie,
personal communication). Staining of P450 proteins was
Control
After TCPOBOP
treatment
(i) CYPlA
often found to be heterogeneous, with some areas of tumour
staining strongly, while others were weak or even negative.
Good agreement was obtained between the levels of protein
detected on Western blot analysis and immunohistochemical
staining.
Evidence that induction ofCYP2Bprotein expression by
TCPOBOP occurs at the level oftranscription
CYP2B mRNA levels were determined in the human colon
xenograft by Northern blot analysis using a cDNA probe for
human CYP2B6 (Figure 3). Two bands of 3.0 kb and 1.65 kb
respectively were detected in both the human liver mRNA
and the xenograft samples. Cyp2b mRNA isolated from the
liver of the host mouse had a much smaller transcript size
(1.5 kb), and was clearly distinguishable from the mRNA
species identified in the tumour tissue. It is interesting to note
that the predominant mRNA species induced in the tumour
tissue is the 3.0 kb transcript, while that in the liver runs at
1.65 kb. This supports the possibility that the major inducible
P450 isozyme within the tumour is distinct from CYP2B6,
but is from the same gene family.
CYP2B mRNA from both the liver of the host mouse and
the associated xenograft tumour was highly induced on xeno-
biotic treatment. In the liver, induction by TCPOBOP was
far greater than that observed on 3-methylcholanthrene treat-
ment. Within the tumour tissue, however, mRNA levels for
both the 3-methylcholanthrene and TCPOBOP treated
groups were equally induced.
The induction of a CYP2B protein within the xenograft
tumours was confirmed by in situ hybridisation for mRNA
using an oligonucleotide probe derived from the human
CYP2B6 cDNA sequence (Figure 4). This oligonucleotide
has 6 mismatches with mouse Cyp2b9, and would not be
expected to hybridise to Cyp2b mRNA. These studies
confirmed the localisation of P450 mRNA to the human
breast and colon tumour cells and, in agreement with the
Northern blot analysis, indicated that the observed induction
of CYP2B protein had occurred at the level of transcrip-
tion.
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Figure 2 Immunohistochemical localisation of cytochrome P450 proteins in control and TCPOBOP-treated animals. P450
expression in xenograft colon a, and breast b, tumours was determined using antibodies against rat (i) CYP1A2 (reactive with both
CYPlAl and CYP1A2) (ii) CYP2B1 and (iii) CYP4A1 proteins. Experimental details were as described in Materials and methods.
Control tumours showed low or negative expression except for breast which expressed CYP2B at low levels and colon which
demonstrated focal reactivity for CYPIA. Treated breast tumours demonstrated strong reactivity for all three antibodies. Induction
of CYP4A was less marked in colon and the expression of CYPIA in treated colon tumour remained very heterogeneous.REGULATION OF CYTOCHROME P450 GENE EXPRESSION 61
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Figure 3 Analysis of CYP2B mRNA levels in a xenograft colon
tumour Northern blot anlysis of mRNA levels was as described
in Materials and methods. Animals were treated intraperitoneally
with either vehicle alone, or with 3-MC or TCPOBOP. HL=
human liver RNA C Control xenograft or xenografts from
MC =3-methylcholanthrene (100 mg kg-'), TC, TCPOBOP
(3 mg kg-') or TC2 =TCPOBOP (15 mg kg-') treated animals.
a
c
Figure 4 Detection of CYP2B mRNA in the tumour xenografts
by in situ hybridisation. In situ hybridisation was carried out
using oligonucleotide probes derived from Exon 2 of the human
CYP2B6 gene, as described in Materials and methods. a, Breast
xenograft from control animals using the antisense oligonucleo-
tide probe showing little significant labelling; b, TCPOBOP-
treated breast xenograft using antisense probe showing wide-
spread, but heterogeneous cytoplasmic reactivity; c, TCPOBOP-
treated colon xenograft using a sense probe, showing no specific
binding; d, TCPOBOP treated colon xenograft using antisense
probe showing strong, fairly homogeneous cytoplasmic reac-
tivity.
A model is described which can be applied to study how
environmental and hormonal factors regulate the expression
of human cytochrome P450 enzymes. The strength of this
model is that it circumvents the previously intractable prob-
lem that the expression and induction of cytochrome P450
expression in cell lines is lost, possibly due to methylation of
the cytochrome P450 genes (Antequara et al., 1990). It also
allows humoral or metabolic factors such as the effects of
hormones and lymphokines which can not be easily studied
in in vitro systems to be evaluated.
Although the influence of the mouse host on the experi-
mental results cannot be ruled out, the observed changes in
gene expression were clearly seen within the human tumour
tissues and therefore reflect the responsiveness of human cells
to the administered agents. Both the tumour tissues studied
maintained their human phenotype and are characteristic of
the tumour tissue of origin.
The data presented here demonstrate that human breast
and colon tumours constitutively express low levels of certain
cytochrome P450 isozymes. This is in agreement with
previous findings which demonstrate that P450 expression is
detectable in tumour biopsy samples from these tissues
(Senler et al., 1985; Forrester et al., 1990; Murray et al.,
1991). The constitutive expression of a protein in the CYP2A
gene family in both the breast and colon samples is interest-
ing in view of the recent report of the isolation of a CYP2A
protein from mouse liver tumours (Maurice et al., 1991).
Evidence is presented that cytochrome P450 levels in
human colon and breast tumour tissues can be influenced by
environmental agents. The patterns of gene regulation
observed were often consistent with what is known about
hepatic P450 regulation in rats and mice. These data imply
that human breast and colon tissues have the capacity to
express P450s from many of the gene families involved in
foreign compound metabolism. Some of the proteins
identified in the xenograft tissues had different mobilities on
SDS-PAGE from the human hepatic P450s. Whether these
proteins represent novel enzymes is currently being investi-
gated.
Of particular interest in this study was the capacity of
dexamethasone and TCPOBOP to induce human tumour
P450 expression. The marked species specificity in the
capacity of these compounds to induce CYP2B and CYP2C
proteins raised the question of whether they would also be
active in man. Both compounds however, especially TCPO-
BOP, had marked effects on the expression of many human
cytochrome P450 isozymes, particularly in the induction of
CYP2B and CYP4A proteins. Immunohistochemistry and in
situ hybridisation studies demonstrated that the induction of
CYP2B occurred within human tissue and indicated that it
occurred either at the level of transcription or message
stabilisation.
It is conceivable that the species-specific effects of TCPO-
C BOP are due to effects on another tissue such as the pituitary
and that this compound may still be inactive in man. This is
unlikely to be the case however, as we have shown that
TCPOBOP-mediated P450 induction in the liver is due to
direct action on hepatocytes (Smith et al., 1992). Species
differences in the metabolism of TCPOBOP to the active
inducer could also explain the specificity of this compound.
* However, this also seems unlikely as TCPOBOP is an inert
compound, and there is no evidence that metabolism is
required before it exerts its inductive effects (Poland et al.,
1980). The immunohistochemical data unequivocally con-
firms that TCPOBOP has the capacity to alter human gene
expression.
The profound induction of CYP4A proteins in the human
breast tumour by TCPOBOP and dexamethasone, and to a
lesser extent by phenobarbital, is intriguing. There are cur-
rently no reports on CYP4A expression in either colon or
breast tissue. The metabolic consequences of CYP4A regula-
tion in these tissues, the expression of which is associated
with peroxisome proliferation and fatty acid metabolism,62 C.R. WOLF et al.
remains to be elucidated.
Mechanisms of regulation of human P450s in extra-hepatic
tissues, by agents other than polycyclic aromatic hydrocar-
bons (McLemore et al., 1990; Vang et al., 1991; Stralka &
Strobel, 1991), are essentially unknown. The xenograft model
allows questions relating to this previously intractable prob-
lem to be addressed. Although animal models have previous-
ly shown that colon tissue will respond to compounds such
as phenobarbital (Degawa et al., 1991; Hammond & Strobel,
1990), the particular P450 isozymes affected are poorly char-
acterised. A similar situation exists for rodent mammary
tissues. It remains to be established how closely P450 regula-
tion within tumour tissues reflects that of the normal tissue
of origin. It has been demonstrated, however, that tumour
cell lines, as well as rat hepatic preneoplastic lesions, retain
many of the transcription factors required for P450 induction
(Buchmann et al., 1987; Vang et al., 1991), the loss of
expression being possibly due to DNA methylation (Ante-
quara et al., 1990).
Finally, these studies demonstrate that exogenous agents
have the capacity to alter human tumour cytochrome P450
levels. This has a variety ofimplications. Firstly, individuality
in the expression of tumour P450 levels may relate to the
responsiveness of patients to chemotherapeutic agents which
are metabolised by this enzyme system. Secondly, the ability
to modulate tumour P450 levels raises the possibility that the
efficacy of chemotherapeutic agents which require P450-
mediated activation in order to exert their anti-tumour effects
could be increased by prior or concomitant administration of
drugs which induce intra-tumour P450 expression. Of partic-
ular interest in this regard are cyclophosphamide, Tamoxifen
and the novel morpholinodoxorubicin derivatives. These
compounds require bioactivation by specific cytochrome
P450 isozymes (Powis & Prough, 1987; Jalacot et al., 1991;
Mani & Kupfer, 1991; Lewis et al., 1992) which we found
inducible within the human tumours by TCPOBOP.
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TCPOBOP, 1,4 bis 2-(3,5 dichloropyridyloxy)benzene; P-NF, P-
naphthoflavone; 3-MC, 3-methylcholanthrene; P450, cytochrome
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